图书馆订阅: Guest
医药载体系统评论综述

每年出版 6 

ISSN 打印: 0743-4863

ISSN 在线: 2162-660X

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.7 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 3.6 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.8 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00023 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.39 SJR: 0.42 SNIP: 0.89 CiteScore™:: 5.5 H-Index: 79

Indexed in

Current Status of DNA Vaccines and Their Route of Administration

卷 19, 册 4-5, 2002, 84 pages
DOI: 10.1615/CritRevTherDrugCarrierSyst.v19.i45.20
Get accessGet access

摘要

This review is aimed at bringing DNA vaccines into perspective with regard to other currently available vaccines and vaccine strategies in development. It is concluded that, encouragingly, DNA vaccines still offer significant potential, with more recent developments such as improved vectors and delivery systems likely to have an important impact; and in addition, the potential safety of DNA as a vaccine is becoming increasingly apparent. Strategies for oral delivery may be suitable for some applications, with all nonparenteral routes likely to require suitable carriers or adjuvants. The diversity of experimental data attests to the increasing interest in vaccination for the treatment and prevention of disease.

对本文的引用
  1. Alpar H Oya, Papanicolaou Irene, Bramwell Vincent W, Strategies for DNA vaccine delivery, Expert Opinion on Drug Delivery, 2, 5, 2005. Crossref

  2. Moschos SA, Bramwell VW, Somavarapu S, Alpar HO, Adjuvant synergy: The effects of nasal coadministration of adjuvants, Immunology & Cell Biology, 82, 6, 2004. Crossref

  3. Sacco Randy E, DNA vaccines against infectious agents: recent strategies for enhancing immune responses, Expert Opinion on Therapeutic Patents, 18, 4, 2008. Crossref

  4. Wilson Kaley D., de Jong Susan D., Kazem Mikameh, Lall Ryan, Hope Michael J., Cullis Pieter R., Tam Ying K., The combination of stabilized plasmid lipid particles and lipid nanoparticle encapsulated CpG containing oligodeoxynucleotides as a systemic genetic vaccine, The Journal of Gene Medicine, 11, 1, 2009. Crossref

  5. Bramwell Vincent W, Perrie Yvonne, Particulate delivery systems for vaccines: what can we expect?, Journal of Pharmacy and Pharmacology, 58, 6, 2010. Crossref

  6. Bramwell Vincent W., Perrie Yvonne, The rational design of vaccines, Drug Discovery Today, 10, 22, 2005. Crossref

  7. Perrie Yvonne, Mohammed Afzal R., Kirby Daniel J., McNeil Sarah E., Bramwell Vincent W., Vaccine adjuvant systems: Enhancing the efficacy of sub-unit protein antigens, International Journal of Pharmaceutics, 364, 2, 2008. Crossref

  8. Zhang Lei, Widera Georg, Bleecher Susan, Zaharoff David A., Mossop Brian, Rabussay Dietmar, Accelerated Immune Response to DNA Vaccines, DNA and Cell Biology, 22, 12, 2003. Crossref

  9. Bowman Katherine, Sarkar Rita, Raut Sanj, Leong Kam W., Gene transfer to hemophilia A mice via oral delivery of FVIII–chitosan nanoparticles, Journal of Controlled Release, 132, 3, 2008. Crossref

  10. Faisal Syed M., Yan WeiWei, Chen Chia-Sui, Palaniappan Raghavan U.M., McDonough Sean P., Chang Yung-Fu, Evaluation of protective immunity of Leptospira immunoglobulin like protein A (LigA) DNA vaccine against challenge in hamsters, Vaccine, 26, 2, 2008. Crossref

  11. Bivas-Benita Maytal, Lin May Young, Bal Suzanne M., van Meijgaarden Krista E., Franken Kees L.M.C., Friggen Annemieke H., Junginger Hans E., Borchard Gerrit, Klein Michèl R., Ottenhoff Tom H.M., Pulmonary delivery of DNA encoding Mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA–PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice, Vaccine, 27, 30, 2009. Crossref

  12. Ho Jenny, Huang Yi, Danquah Michael K., Wang Huanting, Forde Gareth M., Synthesis of biodegradable polymer–mesoporous silica composite microspheres for DNA prime-protein boost vaccination, European Journal of Pharmaceutical Sciences, 39, 5, 2010. Crossref

  13. Lu Dongmei, Hickey Anthony J, Pulmonary vaccine delivery, Expert Review of Vaccines, 6, 2, 2007. Crossref

  14. Esmaeili F., Heuking S., Junginger H.E., Borchard G., Progress in chitosan-based vaccine delivery systems, Journal of Drug Delivery Science and Technology, 20, 1, 2010. Crossref

  15. Somavarapu S., Bramwell V.W., Alpar H.O., Oral Plasmid DNA Delivery Systems for Genetic Immunisation, Journal of Drug Targeting, 11, 8-10, 2003. Crossref

  16. Oya Alpar H., Strategies for Vaccine Delivery, Journal of Drug Targeting, 11, 8-10, 2003. Crossref

  17. Feng C.Y., Li Q.T., Zhang X.Y., Dong K., Hu B.Y., Guo X.K., Immune strategies using single-component LipL32 and multi-component recombinant LipL32-41-OmpL1 vaccines against leptospira, Brazilian Journal of Medical and Biological Research, 42, 9, 2009. Crossref

  18. Branger C., Chatrenet B., Gauvrit A., Aviat F., Aubert A., Bach J. M., André-Fontaine G., Protection against Leptospira interrogans Sensu Lato Challenge by DNA Immunization with the Gene Encoding Hemolysin-Associated Protein 1 , Infection and Immunity, 73, 7, 2005. Crossref

  19. Borchard Gerrit, Esmaeili Farnaz, Heuking Simon, Chitosan‐Based Delivery Systems for Mucosal Vaccination, in Chitosan‐Based Systems for Biopharmaceuticals, 2012. Crossref

  20. Kim Ju, Yang Ye Lin, Jeong Yongsu, Jang Yong-Suk, Application of Antimicrobial Peptide LL-37 as an Adjuvant for Middle East Respiratory Syndrome-Coronavirus Antigen Induces an Efficient Protective Immune Response Against Viral Infection After Intranasal Immunization, Immune Network, 22, 5, 2022. Crossref

Begell Digital Portal Begell 数字图书馆 电子图书 期刊 参考文献及会议录 研究收集 订购及政策 Begell House 联系我们 Language English 中文 Русский Português German French Spain